Virpax Pharmaceuticals, Inc. (VRPX)

US — Healthcare Sector
Peers: PBLA  REVB  PALI  VRAX  QNRX  ZIVO  RNXT  KTTA  ABIO  NTRB  LGVN  BWV  HILS  KPRX  BDRX  PRAX 

Automate Your Wheel Strategy on VRPX

With Tiblio's Option Bot, you can configure your own wheel strategy including VRPX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VRPX
  • Rev/Share 0.0
  • Book/Share -0.2148
  • PB -1.1649
  • Debt/Equity 0.0
  • CurrentRatio 0.63
  • ROIC 9.6021

 

  • MktCap 310874.0
  • FreeCF/Share -3.9284
  • PFCF -0.0186
  • PE -0.0882
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 6.922

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Virpax Pharmaceuticals, Inc. (VRPX)

  • IPO Date 2021-02-17
  • Website https://www.virpaxpharma.com
  • Industry Biotechnology
  • CEO Mr. Jatinder Dhaliwal
  • Employees 2
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.